All Stories

  1. Evaluation of Inflammatory Parameters and Ferritin as Prognostic Factors in Non-small Cell Lung Cancer Patients Receiving Nivolumab Immunotherapy
  2. THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA
  3. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study
  4. LOCALIZE SCROTAL KAPOSI SARCOMA IN A HIV-NEGATIVE PATIENT
  5. Prognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks?
  6. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
  7. Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy
  8. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
  9. BEFORE & AFTER: THE EVALUATION OF THE EFFECT OF THE COVID-19 PANDEMIC ON CANCER PATIENTS IN PALLIATIVE CARE CENTER
  10. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)
  11. The Utility of the Cachexia Index and the Modified Glasgow Score in Young Patients With Breast Cancer
  12. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
  13. Cancer Care After the Earthquake? What Is Left to Us?
  14. The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma
  15. After an Earthquake: The Comparison of Psychological Status of Resident and Earthquake Survivor Cancer Patients
  16. Laboratory Parameters Predicting Brain Metastasis in Patients with Lung Cancer
  17. The efficacy of IMDC score in Malignant Melanoma
  18. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
  19. Kanser hastalarında aşılanma durumu ve aşılanmayı etkileyen faktörlerin değerlendirilmesi
  20. Three Perspectives: The Approach of Neoadjuvant Treatment of Rectum Cancer According to Medical Oncologists, Radiation Oncologists, and Surgeons
  21. A New Prognostic Index in Young Breast Cancer Patients
  22. Microsatellite instability (MSI) in endometrial cancer; frequency and prognostic significance
  23. The Effect of COVID-19 on Radiation Oncology Practice in Türkiye
  24. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
  25. The Effect of The Body Composition to Prognosis in Young Breast Cancer Patients
  26. Prognostic Value of Systemic Immune Index in Patients with Metastatic Gastric Cancer
  27. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
  28. The effect of body composition on prognosis in critically ill COVID-19 patients
  29. Investigation of the Effect of Tumor Location in Patients with Stage III Colon Cancer Receiving Adjuvant Oxaliplatine-Based Adjuvant Chemotherapy
  30. The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer
  31. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
  32. Intravenous Chemotherapy Adherence of Cancer Patients in Time of Covid-19 Crisis
  33. The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study
  34. Adjuvant chemotherapy in gastric cancer
  35. The Effect of The Body Composition to Prognosis in Young Breast Cancer Patients
  36. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
  37. The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment
  38. The Effect of the Prognostic Nutritional Index on Chemoradiotherapy Response in Lung Cancer
  39. P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
  40. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group
  41. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study
  42. Are preoperative serum CA15-3 levels different in breast cancer subgroups?
  43. Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer
  44. Is TTF-1 a prognostic marker in non-small cell lung adenokarsinoma?
  45. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes
  46. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study
  47. Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey.
  48. Cetuximab Treatment for Head and Neck Skin Cancer in a Patient with Heart Transplantation
  49. The Relationship Between the Level of Parathormone and the Existence and the Degree of Coronary Atherosclerosis
  50. Oxaliplatin induced acute immune-mediated thrombocytopenia; a case report